GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Feng Chi Biotech Corp (ROCO:6744) » Definitions » Capex-to-Operating-Cash-Flow

Feng Chi Biotech (ROCO:6744) Capex-to-Operating-Cash-Flow : 0.06 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Feng Chi Biotech Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Feng Chi Biotech's Capital Expenditure for the six months ended in Dec. 2023 was NT$-0.78 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2023 was NT$12.30 Mil.

Hence, Feng Chi Biotech's Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2023 was 0.06.


Feng Chi Biotech Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Feng Chi Biotech's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Feng Chi Biotech Capex-to-Operating-Cash-Flow Chart

Feng Chi Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial 0.19 0.08 0.03 0.01 0.09

Feng Chi Biotech Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 - - 0.20 0.06

Competitive Comparison of Feng Chi Biotech's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Feng Chi Biotech's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Feng Chi Biotech's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Feng Chi Biotech's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Feng Chi Biotech's Capex-to-Operating-Cash-Flow falls into.



Feng Chi Biotech Capex-to-Operating-Cash-Flow Calculation

Feng Chi Biotech's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-1.395) / 15.415
=0.09

Feng Chi Biotech's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.783) / 12.295
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Feng Chi Biotech  (ROCO:6744) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Feng Chi Biotech Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Feng Chi Biotech's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Feng Chi Biotech (ROCO:6744) Business Description

Traded in Other Exchanges
N/A
Address
No. 5, Shaoxing North Street, 5th Floor-1, Zhongzheng District, Taipei City, TWN, 100
Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.

Feng Chi Biotech (ROCO:6744) Headlines

No Headlines